Christopher M. Nutting

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Christopher M. Nutting, James P. Morden, Kevin J. Harrington et al. · The Lancet Oncology · 2011 · 1.7K citations · Full text

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014 · 1.6K citations · Full text

Medicine, Iodine Deficiency Disorders, Radioactive Iodine-refractory +9

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna, Max Robinson, A. Hartley et al. · The Lancet · 2018 · 988 citations · Full text

Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer

Ujjal K. Mallick, Clive Harmer, B. Yap et al. · New England Journal of Medicine · 2012 · 606 citations · Full text

PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer

Hisham Mehanna, Wai‐Lup Wong, Christopher C. McConkey et al. · New England Journal of Medicine · 2016 · 599 citations · Full text